

Gregory Lizã©e

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9312009/publications.pdf>

Version: 2024-02-01

65
papers

6,444
citations

126907

33
h-index

123424

61
g-index

65
all docs

65
docs citations

65
times ranked

10125
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	16.8	115
2	NLR5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy. <i>Scientific Reports</i> , 2021, 11, 3258.	3.3	19
3	Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches. <i>Cancer Discovery</i> , 2021, 11, 1024-1039.	9.4	56
4	Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. , 2021, 9, e002449.		16
5	Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. , 2021, 9, e002531.		24
6	Evolution of CD8+ T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer. <i>Cells</i> , 2021, 10, 2379.	4.1	23
7	Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. <i>Nature Communications</i> , 2020, 11, 5332.	12.8	15
8	HLA-Arena: A Customizable Environment for the Structural Modeling and Analysis of Peptide-HLA Complexes for Cancer Immunotherapy. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 623-636.	2.1	23
9	Markov state modeling reveals alternative unbinding pathways for peptide-MHC complexes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 30610-30618.	7.1	22
10	A phase Ib study of endogenous SLC45A2-specific cytotoxic T cells for the treatment of patients with metastatic uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS10086-TPS10086.	1.6	4
11	Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3K ⁱ Inhibition in PTEN Loss Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 6406-6416.	7.0	35
12	Using parallelized incremental meta-docking can solve the conformational sampling issue when docking large ligands to proteins. <i>BMC Molecular and Cell Biology</i> , 2019, 20, 42.	2.0	22
13	Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3604-3604.	1.6	8
14	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. <i>Clinical Cancer Research</i> , 2018, 24, 3366-3376.	7.0	73
15	General Prediction of Peptide-MHC Binding Modes Using Incremental Docking: A Proof of Concept. <i>Scientific Reports</i> , 2018, 8, 4327.	3.3	41
16	Dynamic changes during the treatment of pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 14764-14790.	1.8	21
17	Next-generation sequencing of Chinese stage IV lung cancer patients reveals an association between EGFR mutation status and survival outcome. <i>Clinical Genetics</i> , 2017, 91, 488-493.	2.0	17
18	SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity. <i>Cancer Immunology Research</i> , 2017, 5, 618-629.	3.4	34

#	ARTICLE	IF	CITATIONS
19	HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. <i>Nature Communications</i> , 2017, 8, 451.	12.8	107
20	DINC 2.0: A New Proteinâ€“Peptide Docking Webserver Using an Incremental Approach. <i>Cancer Research</i> , 2017, 77, e55-e57.	0.9	100
21	Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. <i>Leukemia</i> , 2017, 31, 234-237.	7.2	30
22	Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1210.	4.8	50
23	Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination. <i>Oncolmmunology</i> , 2016, 5, e1238539.	4.6	21
24	Loss of PTEN Promotes Resistance to T Cellâ€“Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	9.4	1,158
25	Trouble at the core: BRAF(V600E) drives multiple modes of T-cell suppression in melanoma. <i>Oncolmmunology</i> , 2016, 5, e1078966.	4.6	8
26	Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma. <i>Sarcoma</i> , 2015, 2015, 1-9.	1.3	48
27	Peptide/MHC Tetramerâ€“Based Sorting of CD8+ T Cells to a Leukemia Antigen Yields Clonotypes Drawn Nonspecifically from an Underlying Restricted Repertoire. <i>Cancer Immunology Research</i> , 2015, 3, 228-235.	3.4	16
28	BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 602-609.	3.4	133
29	Harnessing the Power of the Immune System to Target Cancer. <i>Annual Review of Medicine</i> , 2013, 64, 71-90.	12.2	126
30	BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 1225-1231.	7.0	832
31	Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. <i>Oncolmmunology</i> , 2013, 2, e22691.	4.6	32
32	Strong emerging rationale for combining oncogene-targeted agents with immunotherapy. <i>Oncolmmunology</i> , 2013, 2, e22730.	4.6	7
33	Forging a link between oncogenic signaling and immunosuppression in melanoma. <i>Oncolmmunology</i> , 2013, 2, e22745.	4.6	7
34	BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. <i>Clinical Cancer Research</i> , 2013, 19, 393-403.	7.0	336
35	A Novel HLA-A*0201 Restricted Peptide Derived from Cathepsin G Is an Effective Immunotherapeutic Target in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 247-257.	7.0	33
36	Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant <i>GNAQ</i> and <i>GNA11</i> -Dependent Manner. <i>Clinical Cancer Research</i> , 2012, 18, 4345-4355.	7.0	131

#	ARTICLE	IF	CITATIONS
37	Detection and Characterization of a Novel Subset of CD8+CD57+ T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype. <i>Clinical Cancer Research</i> , 2012, 18, 2465-2477.	7.0	19
38	Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 5329-5340.	7.0	266
39	BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency. <i>Clinical Cancer Research</i> , 2012, 18, 2326-2335.	7.0	109
40	The Role of Antigen Cross-presentation From Leukemia Blasts on Immunity to the Leukemia-associated Antigen PR1. <i>Journal of Immunotherapy</i> , 2012, 35, 309-320.	2.4	37
41	Agonistic Antibody to CD40 Boosts the Antitumor Activity of Adoptively Transferred T Cells In Vivo. <i>Journal of Immunotherapy</i> , 2012, 35, 276-282.	2.4	31
42	Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 6758-6770.	7.0	345
43	PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN- γ Inducible Chemokines. <i>Cancer Research</i> , 2012, 72, 5209-5218.	0.9	351
44	Human Dendritic Cells in Cancer. , 2012, , 121-145.		0
45	Natural Splice Variant of MHC Class I Cytoplasmic Tail Enhances Dendritic Cell-Induced CD8+ T-Cell Responses and Boosts Anti-Tumor Immunity. <i>PLoS ONE</i> , 2011, 6, e22939.	2.5	28
46	Constitutive Aberrant Endogenous Interleukin-1 Facilitates Inflammation and Growth in Human Melanoma. <i>Molecular Cancer Research</i> , 2011, 9, 1537-1550.	3.4	77
47	Identification of Leukemia Associated Antigens From ANKRD17 and CDK4 Using Mass Spectrometry Based Screening,. <i>Blood</i> , 2011, 118, 4020-4020.	1.4	1
48	A Novel HLA-A2 Restricted Peptide Derived From Cathepsin G Is An Effective Immunotherapeutic Target for Myeloid Leukemia. <i>Blood</i> , 2011, 118, 2986-2986.	1.4	0
49	Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses. <i>Clinical Cancer Research</i> , 2010, 16, 5458-5468.	7.0	190
50	A novel strategy for rapid and efficient isolation of human tumor-specific CD4+ and CD8+ T-cell clones. <i>Journal of Immunological Methods</i> , 2008, 331, 13-26.	1.4	15
51	MHC Class I Endosomal and Lysosomal Trafficking Coincides with Exogenous Antigen Loading in Dendritic Cells. <i>PLoS ONE</i> , 2008, 3, e3247.	2.5	72
52	Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 1165-75.	8.2	238
53	Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 5250-5255.	7.0	57
54	IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. <i>International Immunology</i> , 2007, 19, 1213-1221.	4.0	79

#	ARTICLE	IF	CITATIONS
55	HLA-A0201 positive pancreatic cell lines: new findings and discrepancies. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 719-724.	4.2	3
56	Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms. <i>Clinical Cancer Research</i> , 2006, 12, 4794-4803.	7.0	100
57	Immunosuppression in Melanoma Immunotherapy: Potential Opportunities for Intervention. <i>Clinical Cancer Research</i> , 2006, 12, 2359s-2365s.	7.0	33
58	Intralymphatic Dendritic Cell Vaccination Induces Tumor Antigen-Specific, Skin-Homing T Lymphocytes. <i>Clinical Cancer Research</i> , 2006, 12, 5801-5808.	7.0	56
59	A Novel Strategy for Generation of Human Tumor-Specific T Cell Clones for Adoptive Transfer.. <i>Blood</i> , 2006, 108, 3713-3713.	1.4	1
60	Tails of wonder: endocytic-sorting motifs key for exogenous antigen presentation. <i>Trends in Immunology</i> , 2005, 26, 141-149.	6.8	38
61	Lentivirus Vector-Mediated Expression of Tumor-Associated Epitopes by Human Antigen Presenting Cells. <i>Human Gene Therapy</i> , 2004, 15, 393-404.	2.7	63
62	Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo. <i>Cancer Research</i> , 2004, 64, 6783-6790.	0.9	116
63	CD4+ T-Cell Recognition of Mutated B-RAF in Melanoma Patients Harboring the V599E Mutation. <i>Cancer Research</i> , 2004, 64, 1595-1599.	0.9	88
64	Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. <i>Nature Immunology</i> , 2003, 4, 1065-1073.	14.5	166
65	Real-Time Quantitative Reverse Transcriptase-Polymerase Chain Reaction as a Method for Determining Lentiviral Vector Titers and Measuring Transgene Expression. <i>Human Gene Therapy</i> , 2003, 14, 497-507.	2.7	122